The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Cablivi

10 milligram(s) Powder and solvent for solution for injection

Ablynx NVEU/1/18/1305/001

Main Information

Trade NameCablivi
Active Substancescaplacizumab
Strength10 milligram(s)
Dosage FormPowder and solvent for solution for injection
Licence HolderAblynx NV
Licence NumberEU/1/18/1305/001

Group Information

ATC CodeB01AX07 caplacizumab

Status

Authorised/WithdrawnAuthorised
Licence Issued
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing Status

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back